The Serum Institute of India’s R21 Malaria Vaccine has been authorized for use in Nigeria.
During a press conference in Abuja, Professor Mojisola Adeyeye, the NAFDAC Director-General, revealed that the R21 malaria vaccine produced by the Serum Institute of India has received approval from the National Agency for Food and Drug Administration and Control (NAFDAC). With this approval, Nigeria has become the second African country to authorize the use of the vaccine, after Ghana. The R21 malaria vaccine is indicated for the prevention of clinical malaria in children aged 5 months to 36 months. Nigeria is expecting to receive at least 100,000 doses...